Reuters logo
BRIEF-Inotek completes patient recruitment in phase 2 trial of a fixed-dose combination of Trabodenoson and Latanoprost
2017年4月11日 / 上午11点22分 / 7 个月前

BRIEF-Inotek completes patient recruitment in phase 2 trial of a fixed-dose combination of Trabodenoson and Latanoprost

April 11 (Reuters) - Inotek Pharmaceuticals Corp

* Inotek completes patient recruitment in phase 2 trial of a fixed-dose combination (fdc) of Trabodenoson and Latanoprost

* Inotek Pharmaceuticals Corp - Top-line data from FDC study are expected in July Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below